US FDA approves BlackfinBio’s gene therapy trial for hereditary spastic paraplegia
The US Food and Drug Administration has cleared BlackfinBio's investigational new drug (IND) application for a Phase I/II trial of …
Post
-
-
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
ALX Oncology’s CD47-blocker evorpacept, in combination with MSD’s blockbuster Keytruda (pembrolizumab), has failed to show benefit in two Phase II …
-
Kardium reports strong PFA system trial results
Canada-based Kardium has revealed positive one-year efficacy results on its pulsed field ablation (PFA) device, the Globe PF system, at …
-
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial
US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for …
-
MSD reports outcomes from Keytruda combination trial for head and neck cancer
US-based pharmaceutical company MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating resected, locally advanced head …
-
CERo announces SCRI as main site for trial of CER-1236 to treat AML
CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, will be the main site …
-
Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and …
-
Renibus completes enrolment in RBT-1 trial to reduce post-cardiac surgery risk
Renibus Therapeutics has completed subject enrolment for the randomised Phase III PROTECT trial, assessing RBT-1 (stannic protoporfin/iron sucrose) in minimising …
-
Clinical ink introduces AI-powered trial analytics dashboard
Clinical ink has launched the AI-powered, fully integrated analytics dashboard, TrialLens, designed to transform the visualisation, querying, and interpretation of …
-
ESCMID Global 2025: Initial ABI-5366 data supports monthly dosing for genital herpes
Early clinical and preclinical findings presented at the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference …
-
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed …
-
Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS
Tiziana Life Sciences has announced the commencement of dosing in the fourth clinical site of the company’s Phase II trial …
-
Redefining the future of clinical trials in oncology
Next month, experts from big and small pharmaceutical and biotech companies, contract research organisations (CROs), cancer counselling and resource centers …
-
Akeso and Summit notch another Phase III win with their Keytruda competitor
Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary endpoint in a Phase …
-
Cytovation secures $6m for trial of CY-101 to treat adrenocortical carcinoma
Norwegian company Cytovation has secured Nkr62m ($6m) to progress CY-101 into a multi-national Phase II trial, targeting individuals with adrenocortical …
